Сравнение методов
Просматривайте выбранные методы рядом; строки с различиями подсвечены.
| Метааналитическое исследование IV фазы× | Сетевой метаанализ× | |
|---|---|---|
| Область≠ | Эпидемиология | Синтез доказательств |
| Семейство | Process / pipeline | Process / pipeline |
| Год появления≠ | 1990s–2000s (formalised as regulatory requirement context grew) | 2002 |
| Автор метода≠ | Developed through the convergence of meta-analytic methods (Glass, 1976; Hedges & Olkin, 1985) and post-marketing pharmacoepidemiology frameworks | Lumley (2002) |
| Тип≠ | Evidence synthesis applied to post-marketing observational and trial data | Method |
| Основополагающий источник≠ | Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. A., & Song, F. (2000). Methods for Meta-Analysis in Medical Research. Wiley. ISBN: 978-0471490661 | Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324. DOI ↗ |
| Другие названия≠ | Phase IV meta-analysis, post-marketing meta-analysis, pharmacoepidemiologic meta-analysis, post-approval systematic review and meta-analysis | Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis |
| Связанные≠ | 3 | 1 |
| Сводка≠ | A meta-analytic Phase IV study pools and quantitatively synthesises data from multiple Phase IV (post-marketing) sources — including observational cohorts, registries, spontaneous adverse-event databases, and post-approval randomised trials — to produce a single, more precise estimate of a drug or device's real-world effectiveness, safety, or utilisation pattern. By applying meta-analytic weighting to heterogeneous post-marketing evidence, it bridges the gap between tightly controlled pre-approval trials and the complexity of routine clinical practice. | Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied. |
| ScholarGateНабор данных ↗ |
|
|